A Multi-centre, Randomised, Double-blind (Sponsor Open), Placebo-controlled, Repeat Dose, Proof of Mechanism Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of GSK3050002 in Subjects With Psoriatic Arthritis
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 18 Jul 2017
At a glance
- Drugs GSK 3050002 (Primary)
- Indications Psoriatic arthritis
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 18 Jul 2017 Planned End Date changed from 10 Aug 2018 to 9 Aug 2019.
- 18 Jul 2017 Planned primary completion date changed from 10 Aug 2018 to 9 Aug 2019.
- 18 Jul 2017 Planned initiation date changed from 1 Jun 2017 to 1 Jun 2018.